Hyperfine outperforms NeurAxis in 7 of 12 factors in a small-cap medical company comparison.
Hyperfine (HYPR) edges NeurAxis (NRXS) in a head-to-head comparison of various factors, including potential upside, price-to-earnings ratio, and institutional ownership. Hyperfine has a higher consensus target price ($2.12) with a possible upside of 155.88%, while NeurAxis has higher earnings but lower revenue. Hyperfine outperforms NeurAxis in 7 of 12 factors compared between the two small-cap medical companies.
May 07, 2024
3 Articles